Illumina ( ILMN) numbers were increased at Citigroup. Earnings estimates were raised given revenue momentum and sequencing demand, said Citigroup. Price target goes to $85.

Juniper ( JNPR) numbers were raised at Topeka. Shares are now seen reaching $26.75, according to Topeka Capital. Company appears to be on the path to recovery and offered a solid outlook, Topeka said. Buy rating.

Manhattan ( MANH) estimates, price target were increased at Benchmark. Estimates were raised through 2014. Company is cutting costs and seeing higher currency gains, Benchmark said. Hold rating and new $75 price target.

Penn National ( PENN) numbers were lowered at Sterne Agee. Earnings estimates were lowered on decreased guidance and a second-quarter miss, said Sterne Agee. Price target decreased to $60.

Everest Re ( RE) numbers were raised at UBS. Earnings estimates were increased given the first-quarter beat and improved accident year profitability, said UBS. Price target was raised to $150.

United Technologies ( UTX) numbers were raised at Sterne Agee. Shares are now seen reaching $128. Estimates were also increased, as the company is seeing higher orders, said Sterne Agee. Buy rating.

VMware ( VMW) estimates were raised at UBS. Earnings estimates were increased given solid license growth undercurrents, said UBS. Price target is $105.

VMWare ( VMW) estimates, price target were increased at BMO Capital. Earnings estimates were raised through 2014. Company is seeing solid growth across the board, BMO Capital said. Market Perform rating and new $87 price target.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

T-Mobile and Sprint Reportedly Agree on a Deal to Split Ownership

Cord Cutters Aren't Just Leaving Pay-TV Because of Price

Disney Gets Bullish Report Aimed at Drowning Out Naysayers

Market Signals Change of Direction: Cramer's 'Mad Money' Recap (Monday 9/18/17)

U.S. Concrete, Alder Biopharmaceuticals: 'Mad Money' Lightning Round